- Home
- RCT vs CNTX Comparison
RCT vs CNTX Comparison
Compare RCT & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCT
- CNTX
- Stock Information
- Founded
- RCT 2014
- CNTX 2015
- Country
- RCT United Kingdom
- CNTX United States
- Employees
- RCT N/A
- CNTX N/A
- Industry
- RCT
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- RCT
- CNTX Health Care
- Exchange
- RCT NYSE
- CNTX Nasdaq
- Market Cap
- RCT 68.6M
- CNTX 78.0M
- IPO Year
- RCT 2025
- CNTX 2021
- Fundamental
- Price
- RCT $1.73
- CNTX $0.58
- Analyst Decision
- RCT Strong Buy
- CNTX Strong Buy
- Analyst Count
- RCT 2
- CNTX 4
- Target Price
- RCT $5.00
- CNTX $6.00
- AVG Volume (30 Days)
- RCT 32.4K
- CNTX 164.6K
- Earning Date
- RCT 05-17-2025
- CNTX 05-07-2025
- Dividend Yield
- RCT N/A
- CNTX N/A
- EPS Growth
- RCT N/A
- CNTX N/A
- EPS
- RCT N/A
- CNTX N/A
- Revenue
- RCT $46,499,285.00
- CNTX N/A
- Revenue This Year
- RCT N/A
- CNTX N/A
- Revenue Next Year
- RCT N/A
- CNTX N/A
- P/E Ratio
- RCT N/A
- CNTX N/A
- Revenue Growth
- RCT 134.76
- CNTX N/A
- 52 Week Low
- RCT $1.23
- CNTX $0.49
- 52 Week High
- RCT $5.00
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- RCT N/A
- CNTX 27.74
- Support Level
- RCT N/A
- CNTX $0.66
- Resistance Level
- RCT N/A
- CNTX $0.71
- Average True Range (ATR)
- RCT 0.00
- CNTX 0.08
- MACD
- RCT 0.00
- CNTX -0.02
- Stochastic Oscillator
- RCT 0.00
- CNTX 24.19
About RCT REDCLOUD HOLDINGS PLC
RedCloud Holdings PLC developed and operate the RedCloud Platform, that facilitates the trading of everyday consumer supplies of fast-moving consumer goods (FMCG) products across business supply chains. The Platform solves old problem of how to unlock and enable access of key purchase and sales data between brands, distributors and retailers in growth consumer markets. Its Platform has AI and machine learning capabilities that provide brands, distributors and retailers with trading and product insights and data to help, make commercial decisions regarding their business operations. Geographically, Key revenue is generated from Nigeria.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.